Modifications of thermoregulation in patients with suprasellar pituitary adenomas.
R. Behr, G. Hildebrandt, M. Koca and K. Brück 697


Deficits in strategy application following frontal lobe damage in man. T. Shallice and P. W. Burgess 727

Basal temporal language area. H. Lüders, R. P. Lesser, J. Hahn, D. S. Dinner, H. H. Morris, E. Wyllie and J. Godoy 743

Illusions of head and visual target displacement induced by vibration of neck muscles. J. L. Taylor and D. I. McCloskey 755


A historic case of visual agnosia revisited after 40 years. S. A. Sparr, M. Jay, F. W. Drislane and N. Venna 789

Patterns of blood-brain barrier breakdown in inflammatory demyelination. C. P. Hawkins, F. MacKenzie, P. Tofts, E. P. G. H. du Boulay and W. I. McDonald 801

Cerebral akinetopsia (visual motion blindness). A review. S. Zeki 811


Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. J. A. Kiernan and A. J. Hudson 843


Double dissociation of short-term and long-term memory for nonverbal material in Parkinson’s disease and global amnesia. A further analysis. E. V. Sullivan and H. J. Sagar 893

Contents continued on back cover
Edited by P. K. THOMAS

Deputy Editor L. WEISKRANTZ

with the help of

E. BISIACH
L. L. IVERSEN
J. M. NEWSOM-DAVIS

D. Y. von CRAMON
K. KRISTENSSON
E. PIERROT-DESEILLIGNY

L. W. DUCHEN
W. I. MCDONALD
MARCUS E. RAICHEL

M. J. G. HARRISON
C. D. MARSDEN
T. A. SEARS

Assistant Editor E. MACDOUGALL

Secretary and Treasurer D. A. S. COMPSTON

All editorial correspondence, typescripts and books for review to be addressed to The Editor of Brain, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG.

Subscriptions


Reduced rates are available for personal subscribers. For further details please contact the Journals Subscriptions Department. Prices include postage by surface mail or, for subscribers in the USA, Canada, Japan, Australia, New Zealand and India, by Air Speeded Post. Airmail rates are available on request. Back issues are sold at the current single issue rate and complete back volumes are sold at the current single issue rate multiplied by the number of issues in the volume.

Orders

Payment is required with all orders and subscriptions are accepted and entered by the volume(s). Payment may be made by the following methods:

Cheque (made payable to Oxford University Press)
National Girobank (Account 500 1056)
Credit card (Access, Visa, American Express, Diners Club)
UNESCO Coupons

Bankers: Barclays Bank plc, P.O. Box 333, Oxford, UK. Code 20-65-18, Account 00715654

Please send orders and requests for sample copies to: Journals Subscriptions Department, Oxford University Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JL, UK.

Inquiries about advertising, offprints and copyright should be sent to the Journals Production Department, Oxford University Press (address as above).

Brain (ISSN 0006-8950) is published bi-monthly by Oxford University Press, Southfield Road, Eynsham, Oxford OX8 1JL, England. Annual subscription price in USA $195.00 including air speeded delivery. Second class postage paid at Jamaica, NY 11431.

USA POSTMASTERS: Send address changes to Brain, Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003. Air freight and Mailing in the USA by Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003.

Instructions to authors

PAPERS must be typewritten on one side of the paper only. They should be double-spaced, including text, tables, legends and references. If prepared on a word processor, papers printed with a low resolution dot-matrix type will not be considered. In addition to the full title of the paper, authors should supply a running title which will appear at the heads of the pages. This should not exceed forty characters, including spaces. A short summary, to appear at the beginning of the paper, should also be provided.

Brain will consider for publication articles on clinical neurology and neuropsychology, and on basic neuroscience if relevant to the understanding of neurological disorders. Studies purely on normal material are not usually accepted. Brain does not publish preliminary reports of work in progress, brief reports on single cases or correspondence. More detailed studies on single cases will be considered if they lead to significantly new insights or principles. Papers reporting experiments on patients or healthy volunteers must record the fact that the subjects' informed consent was obtained, according to the Declaration of Helsinki (Brit. Med. J., 2, 177). Experiments on animals must conform to accepted ethical standards. Review articles, if authoritative and topical, will also be considered. Four copies of the paper must be submitted. These will not be returned if the paper is not accepted for publication. The illustrations will be returned if a request is made at the time of submission. Should the paper be accepted subject to revision, four copies of the revised version must be submitted. At the time of the initial submission, the paper must be accompanied by the following declaration: 'The work reported in the attached paper entitled ... has not been, and is not intended to be, published anywhere except in Brain'. It must be signed by all authors. Previous publication of the results in abstract form will not preclude consideration.

Continued on inside back cover
Controlling seizures, changing lives

More and more patients with epilepsy are benefitting from the dramatic effect of SABRIL on seizure control. SABRIL reduces seizure frequency in uncontrolled epilepsy by >50% in approximately 50% of patients and some remain completely seizure free.¹

SABRIL
VIGABATRIN

Specific GABA-transaminase inhibition for uncontrolled epilepsy

MERRELL DOW

¹ Abridged prescribing information and references appear on the following page.
Abridged Prescribing Information

SABRILT Tablets

Presentation: White tablets with a breakline marked SABRIL, each containing 500mg vigabatrin.

Uses:
- Treatment of epilepsy not controlled by other antiepileptic drugs.

Dosage and Administration:
- Oral administration once or twice daily added to the patient's current therapeutic regimen.

Adults: Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy.

Children: Recommended starting dose 1g/day in ages 3-9 years and 2g/day if older.

Elderly: Consider dose reduction in patients with impaired renal function.

Contra-Indications, Precautions, Warnings etc

- Use in pregnancy and lactation: Contra-indicated.
- Precautions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60mL/min. Reduce dose and monitor closely for adverse events.
- Warnings: Vigabatrin causes intramyelinic oedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full product data sheet.

Side effects: Anon annoy CNS related. Agitation and psychoses have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: Drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache, and less common confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Some children may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight decrease in haemoglobin.

Drug Interactions: Are unlikely. A gradual reduction in about 20% in plasma phenytoin concentration has been observed. No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.

Legal Category: POM

Package Quantities: Blister strips of 10 in cartons of 100.

Product Licence Number: PL 4425/0098

NHS Price: £45.00

Date of Preparations: November 1990.

You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder:

Merrell Dow Pharmaceuticals Ltd., Lakeside House, Stockley Park, Uxbridge, Middlesex, UB11 1BE

References:
NeuroScan offers more features, flexibility and power than any other EEG/EP system for half the cost. Just compare our advanced, easy to use systems, then make that important purchasing decision.

**SCAN—AN EEG/EP WORKSTATION**

**ACQUISITION.** Continuous or epoch based acquisition of 1-32 channels • Short to long latency EP acquisition • Variable pre- and post-stimulus sampling intervals • Simultaneous display of average and raw EEG of all channels • Bipolar montages • Sweep-triggered internally, externally or by voltage criteria on any channel for backwards averaging • Storage of continuous data, single sweeps and averages • Automatic single sweep identification for later sorting on task variables • Circulating input buffer enables pre-stimulus sampling on externally initiated sweeps • Output to control external devices • Baseline correction • Variable artifact rejection from any combination of channels • Patient information and acquisition parameters included in disk files • Negative displayed up or down • Configuration files for rapid setup of frequently used parameters.

**EDITING AND SIGNAL PROCESSING.** Digital signal processor provides rapid (10ms FFT) processing • Digital filtering • Segment continuous data into epochs • Review of individual sweeps with manual accept/reject • Pre-acquisition averaging in the time or frequency domain • Complete spectrum or user defined bands • Variance computation for statistical analysis • Offline common reference averaging, baseline correction, linear detrending and artifact rejection • User selectable sweep inclusion/exclusion criteria for sorting on task conditions • External sequencing file override for advanced single trial sorting on external task conditions • Relative EEG • Mean frequency analysis • Search on artifact free single sweep editing • Vertical and horizontal scalar artifact removal.

**STATISTICS.** Construction of individual/group averages • Waveform additions and subtractions • Pearson correlation • Intraclass correlation • Group and paired t-scores • Covariance analysis • F-scores • MANOVA • Amplitude normalization • Data import and export to BESA and most statistical packages • All possible bipolar electrode comparisons with waveform and statistical operations.

**MAPPING.** Cartooning of waveforms and spectra • Zoom in to create large individual maps • Display of standard EEG bands • Laplacian transform • Spike mapping • Map report generator • Continuous ‘movie’ map display • Left/right sagittal map views • User designed maps with map template editor for customized maps with different montages • Gray scale maps • Variable number of interpolated points • Map electrode addition, removal, repositioning and renaming • Graphics based editor to create customized map displays.

**BESA**

**BRAIN ELECTRIC SOURCE ANALYSIS.** Singular value decomposition (Principle Components Analysis) to estimate underlying number of sources • Manual localization and testing of dipole configurations • Automatic determination of dipole source potentials for each source configuration • Automatic analysis of dipole source parameters (up to 12 simultaneously) • Rotation of regional dipole sources for optimal adaptation to cortical folding • Moving dipole solution can be computed in selected interval for comparison • Automatic anti-aliasing filtering of raw data • Digital filtering • Support of digital signal processing for increased speed • Modeling up to 64 channels • Source solutions to ASCII file and interface to SCAN.

**STIM**

**SENSORY STIMULATION AND BEHAVIORAL TASKS.** Contrast reversal • Complete range of auditory stimulation from simple clicks for BAER to complex natural auditory stimulation • Control of external devices such as squamous acoustic stimulators • Flexible auditory and Visual P300 task generator • Wide range of traditional neuropsychological tasks and advanced cognitive tasks (i.e. memory and attention) interfacing seamlessly to EP/EEG acquisition • Graphics based digital sound sampler and editor to control and manipulate auditory stimulation • Graphics based visual editor constructs simple and complex color graphic visual stimuli.

AVAILABLE AS A COMPLETE SYSTEM OR AS SOFTWARE ONLY. AMPLIFIERS UP TO 32 CHANNELS (ANY INCREMENTS OF 4 CHANNELS) OR CONNECT TO YOUR EXISTING EEG AND EP EQUIPMENT.

**NEUROSCAN, INC.**

A Neusoft, Inc. Company

1035 Sterling Road / Suite 103 / Herndon, Virginia 22070
(703) 787-7575 / Fax: (703) 787-0297
Receptor Binding Harvesters

Brandel Cell Harvesters for Receptor Binding Assays, Blastogenesis, Mediated and Antibody-Mediated Cytotoxicity Studies of Platelet Antibodies, etc.

- The most versatile and adaptable harvesters available.
- Harvest 12, 24, 36, 48 or 96 wells simultaneously.
- Harvesting probes for flat, round or V-bottom well plates or test tubes.
- Flow adjustment for individual wells.
- Perforates own filter discs from low cost filter sheets.
- All perspex construction — process clearly visible, TCA resistant.
- All components replaceable.
- Ready for use, complete with all tubing, vials, filter paper etc.
- Accessories include wash timer, multi-wash system, hot cold collection valve.

Superfusion Revolution

Introducing the Brandel Superfusion 20 — the first fully automated system for radioactive labeled IgG release studies.

- Multi-channel design allows simultaneous perfusion of 20 tissue samples with up to 6 different reagents.
- Chemical or chemical/electrical superfusion.
- Optional electrical stimulation variable from 0-100mA per channel.
- Computer control, manual operation or manual interrupt with auto resume.
- Microprocessor controlled timing, flow rates and sequence of events ensures accurate and consistent procedure.
- Easy to use menu driven software.
- Reagent and reaction environments water jacketed for optimum temperature control.
- Models for standard 20 x 20 racks of 5-7 ml vials, or 18 x 18 Beckman scintillation racks.
- 6 or 12 channel, semi-automatic version now available.

Oxford Journals

Journal of Neuroendocrinology

Editor-in-Chief: Stafford Lightman

The journal provides prompt publication of high quality research at the interface of neurosciences and endocrinology, and of topical reviews of new ideas, knowledge and technology. International receiving editors ensure rapid review and the highest quality papers from scientists worldwide.

Subscription rates Vol. 3, 1991, 6 issues
UK and Europe £140.00
Rest of World US$275.00
Special rates for BNG, ENA and Society for Neuroscience members

The European Journal of Neuroscience

Editor-in-Chief: R.W. Guillery

Published on behalf of the European Neuroscience Association the journal is of broad scope, ranging from the behavioural to the molecular. The expert international editorial board represents all major areas of research. Published monthly, it is essential reading for all researchers.

Subscription rates Vol. 3, 1991, 12 issues
UK and Europe £215.00
Rest of World US$395.00
Special rates for ENA and Society for Neuroscience members.

For subscription details or FREE sample copies, please write to: Journals Marketing Department (N4), Oxford University Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK
Modifications of thermoregulation in patients with suprasellar pituitary adenomas.
R. Behr, G. Hildebrandt, M. Koca and K. Brück


Deficits in strategy application following frontal lobe damage in man. T. Shallice and P. W. Burgess

Basal temporal language area. H. Lüders, R. P. Lesser, J. Hahn, D. S. Dinner, H. H. Morris, E. Wyllie and J. Godoy

Illusions of head and visual target displacement induced by vibration of neck muscles. J. L. Taylor and D. I. McCloskey


A historic case of visual agnosia revisited after 40 years. S. A. Sparr, M. Jay, F. W. Drislane and N. Venna

Patterns of blood-brain barrier breakdown in inflammatory demyelination. C. P. Hawkins, F. MacKenzie, P. Tofts, E. P. G. H. du Boulay and W. I. McDonald

Cerebral akinetopsia (visual motion blindness). A review. S. Zeki


Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. J. A. Kiernan and A. J. Hudson


Double dissociation of short-term and long-term memory for nonverbal material in Parkinson’s disease and global amnesia. A further analysis. E. V. Sullivan and H. J. Sagar

Contents continued overleaf
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differential effect of compression-ischaemia block on warm sensation and heat-induced pain. D. Yarnitsky and J. L. Ochoa</td>
<td>907</td>
</tr>
<tr>
<td>Experimental vitamin E deficiency in rats. Morphological and functional evidence of abnormal axonal transport secondary to free radical damage. E. Southam, P. K. Thomas, R. H. M. King, M. A. Goss-Sampson and D. P. R. Muller</td>
<td>915</td>
</tr>
<tr>
<td>A neurophysiological comparison of three distinct regions of the primate frontal lobe. G. di Pellegrino and S. P. Wise</td>
<td>951</td>
</tr>
<tr>
<td>Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. P. J. Goadsby and A. S. Zagami</td>
<td>1001</td>
</tr>
<tr>
<td>Processing of spatial relations within and between the disconnected cerebral hemispheres. J. Sergent</td>
<td>1025</td>
</tr>
<tr>
<td>Book reviews</td>
<td>1097</td>
</tr>
<tr>
<td>Announcements</td>
<td>1113</td>
</tr>
</tbody>
</table>